Abstract
The detection of hormone receptors on meningiomas raises the possibility of hormonal manipulation as a form of therapy. Since progesterone receptors are found on meningiomas more frequently and in greater amounts than estrogen receptors, manipulation of progesterone levels would be most promising. A trial of the oral progesterone agonist megestrol acetate for the treatment of unresectable meningioma was therefore performed. Megestrol acetate was administered at a dose of 40 mg four times daily which could be escalated to 80 mg four times daily. Nine patients (six meningothelial, two fibrous, and one anaplastic meningiomas) were treated for 1 to 12 months. No tumor responses were seen. However three patients required discontinuation of therapy due to deteriorating vision within 2 1/2 months. The major systemic toxicity of megestrol acetate was weight gain with a median weight gain of 14 kg for patients treated for at least 6 months. Due to the lack of efficacy and the significant toxicity noted, megestrol acetate is not recommended for the treatment of meningioma. However clinical trials of progesterone antagonists would still be of interest.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Quest DO: Meningiomas: An update. Neurosurgery 3: 219–225, 1978
Bickerstaff ER, Small JM, Guest IA: The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 21: 89–91, 1958
Schoenberg BS, Christine BW, Whisnant JP: Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25: 705–712, 1975
Emry JK: The association between breast cancer and meningiomas. Master's thesis (Biometry), University of Southern California, Los Angeles, California, 1984
Donnell MS, Meyer GA, Donegan WL: Estrogen-receptor protein in intracranial meningiomas. J Neurosurg 50: 499–502, 1979
Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103: 1742–1751, 1978
Schnegg J-F, Gomez F, LeMarchand-Beraud T, de Tribolet N: Presence of sex steroid hormone receptors in meningioma tissue. Surg Neurol 15: 415–418, 1981
Magdelenat H, Pertuiset BF, Poisson M, Martin PM, Phillipon J, Pertuiset B, Buge A: Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases. Acta Neurochir 64: 199–213, 1982
Tilzer LL, Plapp FV, Evans JP, Stone D, Alward K: Steroid receptor proteins in human meningiomas. Cancer 49: 633–636, 1982
Blankenstein MA, Blaauw G, Lamberts SWJ, Mulder E: Presence of progesterone receptors and absence of oestrogen receptors in human intracranial meningioma cytosols. Eur J Cancer Clin Oncol 19: 365–370, 1983
Vaquero J, Marcos ML, Martinez R, Bravo G: Estrogen-and progesterone-receptor proteins in' intracranial tumors. Surg Neurol 19: 11–13, 1983
Whittle IR, Foo MS, Besser M, Vanderfield GK: Progesterone and oestrogen receptors in meningiomas: biochemical and clinicopathological considerations. Aust NZ J Surg 54: 325–330, 1984
Martuza RL, Miller DC, MacLaughlin DT: Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas. J Neurosurg 62: 750–756, 1985
Grunberg SM, Daniels AM, Muensch H, Daniels JR, Bernstein L, Kortes V, Weiss MH: Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay. J Neurosurg 66: 405–408, 1987
Hellman S, Harris JR, Canellos GP, Fisher B: Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer — Principles and Practice of Oncology. JB Lippincott, Philadelphia, 1982, pp 914–970
Markwalder T-M, Seiler RW, Zava DT: Antiestrogenic therapy of meningiomas — a pilot study. Surg Neurol 24: 245–249, 1985
Olson JJ, Beck DW, Schlechte J, Loh P-M: Hormonal manipulation of meningiomas in vitro. J Neurosurg 65: 99–107, 1986
Canetta R, Florentine S, Hunter H, Lenaz L: Megestrol acetate. Cancer Treat Rev 10: 141–157, 1983
Markwalder T-M, Waelti E, Konig MP: Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on receptor status of meningioma cytosols. Surg Neurol 28: 3–9, 1987
Jaaskelainen J, Laasonen E, Karkkainen J, Haltia M, Troupp H: Hormone treatment of meningiomas: Lack of response to medroxyprogesterone acetate (MPA) — A pilot study of five cases. Acta Neurochir 80: 35–41, 1986
Rucker CW, Kearns TP: Mistaken diagnoses in some cases of meningioma. Am J Ophthalmol 51: 15–19, 1961
Weyand RD, MacCarty CS, Wilson RB: The effect of pregnancy on intracranial meningiomas occurring about the optic chiasm. Surg Clin North Am 31: 1225–1233, 1951
Jay JR, MacLaughlin DT, Riley KR, Martuza RL: Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 62: 757–762, 1985
Olson JJ, Beck DW, Schlechte JA, Loh P-M: Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg 66: 584–587, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grunberg, S.M., Weiss, M.H. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neuro-Oncol 8, 61–65 (1990). https://doi.org/10.1007/BF00182088
Issue Date:
DOI: https://doi.org/10.1007/BF00182088